Navigation Links
Field of beams - Novel system uses polarized light pulses to reveal crop health

Mathematical models have become invaluable decision-making tools for public health officials. As demonstrated during the United Kingdom's foot-and-mouth epidemic of 2001, models can be useful in two ways: they can reveal the underlying characteristics of an infection and they can allow the comparison of alternative control measures. Often, however, such models make implicit assumptions that may systematically bias their predictions, say researchers at the University of Georgia.

In a paper published today in the online open-access journal PLoS (Public Library of Science) Medicine, Helen Wearing and Pejman Rohani of the Institute of Ecology at the University of Georgia and Matt Keeling of the University of Warwick, United Kingdom, showed that commonly used disease models may risk making overly optimistic predictions about the levels of public health interventions needed to bring a disease under control.

Wearing and her colleagues found that many off-the-shelf models used in infection management do not realistically account for the length of time that people harbor infections. The simplest models entirely ignore the latent period of a disease: the period of time when an individual is infected but not yet infectious. Other models often assume that the rate of progression from latent to infectious, and infectious to recovered, is constant, irrespective of the time already spent in that status. In such models, for example, many people have a very short infectious period while a few have a very long infectious period. In reality, most people are infectious for an average period of time. For the flu the average infectious period is around 4-5 days, with incredibly few people infectious for less than a couple of days or more than a week.

"Models which do not incorporate the latent period or assume unrealistic distributions of the latent and infectious period," said the researchers, "always resulted in underestimating the transmission potential of an in fection when fitted to initial outbreak data."

The idea for the project came about when the Centers for Disease Control and Prevention approached Rohani to assist in the modeling of potential smallpox introduction. "I noticed that when we assumed different distributions of the infectious period in the models, we observed very different epidemic curves," said the researcher. Conversations with Wearing and Keeling followed, alternative models were compared and data from an influenza outbreak were used to illustrate the potential bias in model predictions.

The impact of such differences on predicting the spread of new, highly transmissible diseases could be important to public health workers, said Wearing. Underestimating the transmissibility of an infection could lead to predicting inadequate levels of disease management, such as contact tracing and quarantining of those exposed. However, Wearing was careful to stress that current health protection programs have shown their effectiveness in such situations as the recent SARS outbreak in Southeast Asia.

"We are highlighting what 'may happen' if we don't pay careful attention to the inherent assumptions in the models that we fit to data," said Wearing. "The key point is that uncertainty about the latent and infectious period distributions should be taken into account when making quantitative predictions for public health use."


'"/>

Source:Containerless Research, Inc. & National Science Foundation


Related biology news :

1. Field tested: Grasslands wont help buffer climate change as carbon dioxide levels rise
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. Novel technology detects human DNA mutations
4. Novel antiviral technology inhibits RSV infection in mice
5. Novel Enzyme Shows Potential As An Anti-HIV Target
6. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
7. Discovery Could Lead To Novel Approaches In HIV Treatment
8. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
9. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
10. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
11. Novel live reporting system to track cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
(Date:12/5/2016)... The U.S. Biotechnology industry is ... of revenue and some $890 billion of total market ... biopharmaceuticals, and this figure is expected to exceed $220 ... these four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... CAMBRIDGE, Mass. and CAPE ... SystemOne, a company focused on connecting ... the developing world, and Daktari Diagnostics, a company ... its portable and ultrasensitive immunoassay-based CarePlatform™, today announced ... license agreement to integrate Daktari,s technology platform with ...
(Date:12/2/2016)... Calif. , Dec. 2, 2016 Amgen (NASDAQ: ... AGN ) today announced the submission of a Marketing Authorization ... 215, a biosimilar candidate to Avastin ® (bevacizumab). The ... submitted to the EMA. "The submission of ... Amgen seeks to expand our oncology portfolio," said Sean ...
Breaking Biology Technology: